Application No.: 10/774,697 3 Docket No.: 20342/1202658-US2

## **LISTING OF THE CLAIMS**

- 1. (Currently amended) A pharmaceutical combination comprising an effective amount for a day of l- and d- amphetamines, each in base and/or salt form, and wherein the molar ratio of l- amphetamine to d-amphetamine released from the pharmaceutical composition combination in a time period later in the day is higher than said ratio released therefrom in a time period earlier in the day.
- 2. (Original) A pharmaceutical combination of claim 1, wherein said earlier period is the time before about 1:00 pm of a given day and said later period is the time thereafter.
- 3. (Original) A pharmaceutical combination of claim 1, wherein said amphetamine released in said earlier period comprises substantially only d-amphetamine, racemic amphetamine, or a mixture of d- and l-amphetamine having more d- than l-amphetamine.
- 4. (Original) A pharmaceutical combination of claim 1, wherein the molar ratio released of dto 1- amphetamine in said earlier period is about 4/1 to about 2/1.
- 5. (Original) A pharmaceutical combination of claim 1, wherein the molar ratio released of dto l- amphetamine in said earlier period is less than 1/1.
- 6. (Original) A pharmaceutical combination of claim 1, wherein substantially only damphetamine is released in said early period.
- 7. (Original) A pharmaceutical combination of claim 1, wherein said amphetamine released in said earlier period comprises a mixture of d- and l-amphetamine having more l- than d-amphetamine.
- 8. (Original) A pharmaceutical combination of claim 1, wherein said amphetamine released in said later period comprises substantially only l-amphetamine, racemic amphetamine, or a mixture of

Application No.: 10/774,697 4 Docket No.: 20342/1202658-US2

d- and l-amphetamine having more l- than d-amphetamine.

- 9. (Original) A pharmaceutical combination of claim 1, wherein said amphetamine released in said later period comprises a mixture of d- and l-amphetamine having more l- than d-amphetamine.
- 10. (Original) A pharmaceutical combination of claim 1, wherein the molar ratio released of 1- to d-amphetamine in said later period is about 2/1 to about 6/1.
- 11. (Original) A pharmaceutical combination of claim 1, wherein substantially only lamphetamine is released in said later period.
- 12. (Original) A pharmaceutical combination of claim 1, wherein the total amphetamine dose per day is about 1 to about 200 mg.
- 13. (Original) A pharmaceutical combination of claim 1, which comprises two separate oral dosage forms, one identified to be administered at a time to provide amphetamine release in said earlier period and the other identified to be administered at a time to provide amphetamine release in said later period.
- 14. (Original) A pharmaceutical combination of claim 1, which comprises a single oral dosage form which provides amphetamine release in both said earlier and later periods.
- 15. (Original) A pharmaceutical combination of claim 1, which comprises a dosage form providing immediate release of d-amphetamine in said earlier period.
- 16. (Currently amended) A method for treating ADHD comprising administering to a human effective amounts of the l- and d-isomers of amphetamine, each independently in free base and/or salt form, and wherein the molar ratio of <u>l-amphetamine to d-amphetamine administered in a time period later in the day is higher than the ratio administered in a time period earlier in the day;</u> the

Application No.: 10/774,697 5 Docket No.: 20342/1202658-US2

total amount of l-isomer to the total amount of d-isomer administered per day is greater than 1:3; and the time period later in the day is at least about one hour following the time period earlier in the day.

- 17. (Original) A method according to claim 16, wherein doses are administered individually at different times or are administered once in a single staged-release dosage form.
- 18. (Original) A method according to claim 16, wherein doses are administered in one or more dosage forms that are either immediate release or pulse release dosage forms and/or sustained or controlled release dosage forms.
- 19. (Original) A method according to claim 18, wherein the sustained or controlled release dosage form or dosage forms contain the l isomer.
- 20. (Previously presented) A method according to claim 16, wherein two doses of amphetamine are administered to the patient in a day, the first dose having an l to d isomer ratio of about 1:3 or contains only d isomer, and the later dose having an l to d isomer ratio of greater than 1:1 or contains l isomer only.
- 21. (Original) A method according to claim 20, wherein the second dose contains I isomer only.
- 22. (Original) A pharmaceutical combination according to claim 1, wherein doses are administered individually at different times or are administered once in a single staged-release dosage form.
- 23. (Original) A pharmaceutical combination according to claim 1, wherein doses are administered in one or more dosage forms that are either immediate release or pulse release dosage forms and/or sustained or controlled release dosage forms.

Application No.: 10/774,697 6 Docket No.: 20342/1202658-US2

24. (Original) A pharmaceutical combination according to claim 23, wherein the sustained or controlled release dosage form or dosage forms contain the l isomer.

- 25. (Previously presented) A pharmaceutical combination according to claim 1, wherein two doses of amphetamine are administered to the patient in a day, the first dose having an l to d isomer ratio of about 1:3 or contains only d isomer, and the later dose having an l to d isomer ratio of greater than 1:1 or contains l isomer only.
- 26. (Original) A pharmaceutical combination according to claim 25, wherein the second dose contains 1 isomer only.
- 27. (Original) A method of treating ADHD in a human comprising administering a pharmaceutical combination of claim 1.
- 28. (Previously presented) A method of treating inattentiveness in an ADHD human patient comprising administering a pharmaceutical combination of claim 1 to said human, wherein the effectiveness of treatment of said inattentiveness in an ADHD human patient later in the day by said 1-isomer is as good as treatment with a corresponding molar amount of d-amphetamine and is accompanied by a lesser side effect of sleep deterioration and/or decrease in food intake.